ArticleBone marrow transplantation2022
Correction to: Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.
Emily C Liang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.